The myth of the stigma of fatty liver: What does the evidence show?

Abstract

Recent efforts to reclassify non-alcoholic fatty liver disease (NAFLD) as metabolic dysfunction-associated fatty liver disease (MAFLD) and metabolic dysfunction-associated steatotic liver disease (MASLD) are intended to divert attention to the metabolic basis of the disease rather than to alcohol consumption. This reclassification recognizes the role of obesity, sedentary lifestyles and poor dietary habits in the development of the disease, leading to a better understanding of its etiology. Nevertheless, the transition has posed its own challenges, particularly with regard to communication between patient and healthcare professional. Many healthcare professionals report difficulty in explaining the nuanced concepts, especially the term ''steatosis''. In addition, the change in terminology has not yet removed the stigma, with ongoing debates about the appropriateness of the terms ''fatty'' and ''steatotic''. Surveys suggest that while ''obesity'' may be perceived as more stigmatizing, the medical term ''steatotic liver disease'' is not considered as stigmatizing, indicating a disconnect in perceptions between healthcare professionals and patients.

Keywords

• NAFLD
• MAFLD
• MASLD
• Obesity
• Disease-related stigma
• Fatty liver